Zanaflex

Legal status and availability in the UK

In our online pharmacy, Zanaflex is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.

Basic Zanaflex information

• INN (international nonproprietary name): Tizanidine.
• Brand names available in the United Kingdom: Zanaflex; generic tizanidine products from Accord Healthcare, Apotex, Teva, Mylan.
• ATC code: M03BX02.
• Forms and dosages: tablets 2 mg and 4 mg.
• Manufacturers: multiple generic manufacturers including Accord Healthcare, Apotex, Teva, Mylan.
• OTC / Rx classification: Prescription (Rx) — Not OTC.

Clinical effectiveness in the UK

Within NHS practice tizanidine is typically a second‑line centrally acting antispasmodic for focal or activity‑limiting spasticity when sedation is acceptable.

Tizanidine can reduce spasm frequency and nocturnal sleep disturbance, especially when combined with physiotherapy.

Long‑term functional gains are variable and often depend on rehabilitation input and comorbidity management.

• Common outcomes: reduced nocturnal spasm, improved sleep, intermittent daytime sedation.
• Adherence challenges: daytime drowsiness and hypotension leading to falls in frail or elderly patients.
• Prescribing practice: cautious low‑dose initiation with documented shared decision‑making.
• Monitoring: hepatic enzyme elevations and interaction‑related adverse events can occur.

Indications and expanded uses (MHRA and off‑label)

MHRA‑aligned practice follows SPC recommendations and generally reserves tizanidine for adult spasticity associated with multiple sclerosis and spinal cord injury.

In private practice clinicians occasionally use tizanidine off‑label for short‑term relief of acute muscle spasm from musculoskeletal strains, but NHS guidance favours licensed indications.

Off‑label use should be documented and consented to; common NHS off‑label scenarios include using tizanidine to facilitate physiotherapy or reduce spasm pre‑botulinum toxin injection.

• Checklist for indication versus off‑label justification: documented diagnosis, treatment goal, duration, consent, monitoring plan.

Absolute exclusions: concomitant fluvoxamine or ciprofloxacin and severe hepatic impairment are contraindications per SPCs.

Composition and brand landscape

The active ingredient is tizanidine (INN).

Clinicians in the UK encounter branded and generic options including Zanaflex, with generics supplied by Accord Healthcare, Apotex, Teva, and Mylan.

The dosage forms are tablets 2 mg and 4 mg.

Note on interchangeability: products may differ in bioequivalence and excipients.

Do not interchange brands arbitrarily without checking the SPC and recording any change in pharmacy notes.

Contraindications and special precautions (high‑risk groups)

Absolute contraindications per SPCs include allergy to tizanidine, severe hepatic impairment, and concomitant use with fluvoxamine or ciprofloxacin.

Relative contraindications requiring close monitoring include hypotension, bradycardia, concurrent CNS depressants, elderly or frail patients, and renal impairment.

• Absolute contraindications: allergy to tizanidine; severe hepatic impairment; concomitant fluvoxamine or ciprofloxacin.
• Relative contraindications: hypotension; bradycardia; concurrent CNS depressants or antihypertensives; elderly or debilitated patients; renal impairment.

Pregnancy

Limited data available; avoid unless specialist advises and benefits clearly outweigh risks.

Breastfeeding

Limited data; seek specialist advice before use and consider alternative agents where possible.

Interaction note: The fluvoxamine and ciprofloxacin combination markedly increases tizanidine levels and is contraindicated in SPCs.

Dosage guidelines (NHS‑aligned regimens and adjustments)

Unsure how tizanidine dosing starts and how it is adjusted?

The usual adult starting dose is 2 mg daily, increased in steps of 2 mg at intervals of at least 3–4 days and given in divided doses, per SPC guidance.

The recommended maximum dose is 36 mg/day for spasticity, though many NHS patients function well on 6–18 mg/day.

Elderly patients and those with hepatic impairment require lower starting doses and slower titration.

Children are generally not recommended due to unestablished safety.

• Monitoring checklist: baseline and periodic BP checks, liver function tests where indicated, assessment of sedation and falls risk.
• Missed dose advice: take when remembered unless near the next dose; do not double up.
• Stopping advice: taper gradually to avoid withdrawal or rebound hypertension.

Interactions overview (drugs and food)

Worried about dangerous interactions with medicines you already take?

Potent CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin markedly increase tizanidine plasma concentrations and are contraindicated.

CNS depressants, antihypertensives and alcohol can potentiate sedation and hypotension with tizanidine.

Food can change absorption timing and tolerability.

SPC reminder: check the current product SPC before starting tizanidine and counsel patients on interaction risks.

Comparable medicines and prescribing preferences (NHS alternatives)

Trying to decide between tizanidine and other muscle relaxants?

NHS prescribers often consider baclofen, diazepam and other centrally acting agents when choosing a therapy for spasticity.

Baclofen is commonly favoured where hepatic interaction risks are a concern, though it can cause sedation and muscle weakness.

Diazepam is used short term because of dependence risk and daytime sedation.

• Choice criteria checklist: comorbidity (liver, hypotension), interaction profile, rehabilitation goals, monitoring burden, patient preference.

Frequently asked questions

Q1: Will tizanidine make me sleepy?

A: Sedation and drowsiness are common; start at a low dose and avoid driving until effects are known.

Q2: Can I drink alcohol while taking it?

A: No; alcohol increases CNS depression and hypotension risk and should be avoided while on therapy.

Q3: What if I forget a dose?

A: Take it when you remember unless the next dose is due soon; do not double the dose.

Q4: How do I get a repeat NHS prescription?

A: Use your GP surgery’s repeat prescription service, the NHS App, or speak to your community pharmacist for advice on monitoring and repeat supply.

Guidelines for proper use (pharmacist counselling and NHS resources)

Explain the indication clearly and set expectations: short‑term relief of spasm and expected side effects such as drowsiness, dry mouth and dizziness.

Highlight interaction risks, especially with fluvoxamine and ciprofloxacin, and advise patients to avoid alcohol.

Advise on dose timing to match symptom pattern and recommend monitoring blood pressure and liver tests where indicated.

• Pharmacist counselling checklist: confirm indication, review current medicines for CYP1A2 inhibitors, advise on driving and alcohol, record brand and monitoring plan in pharmacy notes, signpost Yellow Card and NHS 111.

NHS resources

Yellow Card for adverse reactions and NHS 111 for urgent queries.

Delivery across the United Kingdom